Zacks Investment Research
29 Jun 2026, 18:46 UTC · 15w ago
Impact · against what's priced in
Harmony Biosciences faces a mixed outlook as recent earnings and revenue misses offset a strong balance sheet and reaffirmed guidance. While the stock trades at a significant valuation discount, the lack of diversification beyond Wakix limits the potential for a price re-rating.
No priced-in read yet
What the story claims
4 claims · scored −1 bearish … +1 bullish
Harmony Biosciences (HRMY) reported quarterly earnings of $0.55 per share and net product revenues of $215.4 million, both missing Zacks Consensus Estimates.
More negative than 86% of claims this week
Harmony Biosciences reiterated its 2026 Wakix net revenue guidance of $1.0 billion to $1.04 billion.
So whatReaffirming guidance provides a floor for valuation and signals management's confidence in the primary revenue driver.
Continue reading
5 related stories
The company missed both quarterly earnings ($0.55 per share) and net product revenue ($215.4 million) expectations, though it maintains a strong cash position of $870.5 million and reaffirmed 2026 revenue guidance of $1.0B to $1.04B.
Read from the article alone
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 67% of claims this week
Harmony Biosciences ended Q1 2026 with $870.5 million in cash, cash equivalents, and investments.
More positive than 54% of claims this week
HRMY trades at 10.38x forward 12-month earnings, significantly lower than the S&P 500 (20.9x) and its sub-industry (44.24x).
So whatA significant valuation discount relative to peers may attract value investors despite growth risks.
More positive than 54% of claims this week
Which stocks this story touches
More positive than 57% of ticker scores this week
The company shows strong revenue growth and a solid balance sheet, though recent earnings misses and product concentration create a balanced debate.
Near neutral — 92% of ticker scores this week are stronger
Mentioned only as a neuroscience peer for comparison without specific positive or negative news.
Near neutral — 92% of ticker scores this week are stronger
Mentioned as a relevant specialty pharma comparison without any specific performance news.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
3h ago
More positive than 13% of relationship scores this week
[mutual] Jazz Pharmaceuticals is cited as a relevant specialty pharma comparison for Harmony Biosciences due to its sleep medicine presence.
+7.8%
Price is moving against the score
$38.23 vs $35.47 close before publication (Jun 26) · not market-adjusted
HRMY chart →
